Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Gets OK for Nasdaq Switch

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix today said that the Nasdaq Stock Market has approved the firm's switch to the Nasdaq Capital Market from the Nasdaq Global Market.

The Irvine, Calif.-based molecular diagnostics firm announced last week that it was voluntarily applying for the transfer rather than submitting a plan to the exchange to regain compliance with Nasdaq Global Market listing requirements. The switch will enable the firm to meet the exchange's listing requirement for shareholders' equity.

The transfer will be effective Friday, and CombiMatrix's shares will continue to trade under the symbol "CBMX."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.